Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Relmada Therapeutics Announces Promotions

This article was originally published in Scrip

Executive Summary

Relmada Therapeutics, Inc. has promoted Richard M. Mangano to chief scientific officer and Lisa Nolan to the newly created role of chief business officer. Mangano has experience leading R&D programs and previously held positions in discovery and clinical research at Hoffmann-La Roche, Lederle Laboratories, Wyeth Research, where he was acting therapeutic area director for neuroscience; and Adolor Corp., where he was vice-president of clinical research and development. Previously, Nolan was chief business officer at Topigen Pharmaceuticals, prior to this she was vice-president of global business development and strategic marketing for Skyepharma PLC. Nolan also held various senior positions in business and marketing at West Pharmaceutical Services, Elan Corp., and Zeneca Pharmaceuticals. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC029968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel